C
Calidi Biotherapeutics, Inc. (CLDI)
ASE – Real Time Price. Currency in USD
0.16
+0.01 (8.88%)
At close: Jun 26, 2026, 4:00 PM EDT
0.16
+0.00 (0.37%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.16
+0.01 (8.88%)
At close: Jun 26, 2026, 4:00 PM EDT
0.16
+0.00 (0.37%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D. | Head of Technical Operations & Chief Scientific Officer |
| Dr. Eric E. Poma Ph.D. | CEO & Director |
| Dr. Guy Travis Clifton M.D. | Chief Medical Officer |
| Mr. Andrew C. Jackson | CFO & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-06-18 | 8-K | form8-k.htm |
| 2026-06-05 | DEFA14A | formdefa14a.htm |
| 2026-05-29 | 8-K | form8-k.htm |
| 2026-05-14 | 8-K | form8-k.htm |
| 2026-05-14 | 10-Q | form10-q.htm |
| 2026-05-08 | 8-K | form8-k.htm |
| 2026-04-29 | DEFA14A | formdefa14a.htm |
| 2026-04-29 | DEF 14A | formdef14a.htm |
| 2026-04-17 | PRE 14A | formpre14a.htm |
| 2026-04-02 | 8-K | form8-k.htm |